Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study.

Mavroudis D, Malamos N, Polyzos A, Kouroussis Ch, Christophilakis Ch, Varthalitis I, Androulakis N, Kalbakis K, Milaki G, Georgoulias V; Breast Cancer Study Group of the Hellenic Oncology Research Group (HORG)..

Oncology. 2004;67(3-4):250-6.

PMID:
15557786
2.

Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial.

Mavroudis D, Alexopoulos A, Malamos N, Ardavanis A, Kandylis C, Stavrinidis E, Kouroussis Ch, Agelaki S, Androulakis N, Bozionelou V, Georgoulias V.

Oncology. 2003;64(3):207-12.

PMID:
12697959
3.

Weekly docetaxel and gemcitabine following docetaxel plus epirubicin or vinorelbine as first-line treatment of metastatic breast cancer: results of a multicenter phase II study.

Riccardi A, Brugnatelli S, Danova M, Giordano M, Pugliese P, Luchena G, Grasso D, Trotti G, Bertè R, Pansini G, Tinelli C.

Tumori. 2006 Jan-Feb;92(1):6-12.

PMID:
16683377
4.

Final results of a phase II clinical trial of weekly docetaxel in combination with capecitabine in anthracycline-pretreated metastatic breast cancer.

Mackey JR, Tonkin KS, Koski SL, Scarfe AG, Smylie MG, Joy AA, Au HJ, Bodnar DM, Soulieres D, Smith SW.

Clin Breast Cancer. 2004 Oct;5(4):287-92.

PMID:
15507175
5.

Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor.

Kornek GV, Haider K, Kwasny W, Raderer M, Schüll B, Payrits T, Depisch D, Kovats E, Lang F, Scheithauer W.

Clin Cancer Res. 2002 May;8(5):1051-6.

6.

A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.

Yardley DA, Peacock NW, Dickson NR, White MB, Vázquez ER, Foust JT, Grapski R, Hendricks LK, Scott WL, Hainsworth JD.

Clin Breast Cancer. 2010 Jun;10(3):217-23. doi: 10.3816/CBC.2010.n.029.

PMID:
20497920
7.

Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.

Vassilomanolakis M, Koumakis G, Demiri M, Missitzis J, Barbounis V, Efremidis AP.

Cancer Invest. 2003;21(4):497-504.

PMID:
14533438
8.

Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study.

Ardavanis A, Tryfonopoulos D, Alexopoulos A, Kandylis C, Lainakis G, Rigatos G.

Br J Cancer. 2005 Feb 28;92(4):645-50.

9.

Phase II trial of weekly docetaxel/ gemcitabine as first-line chemotherapy in patients with locally recurrent or metastatic breast cancer.

O'Shaughnessy JA, Pluenneke R, Sternberg J, Khandelwal P, Ilegbodu D, Asmar L.

Clin Breast Cancer. 2006 Feb;6(6):505-10.

PMID:
16595033
10.

Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.

Alba E, Martín M, Ramos M, Adrover E, Balil A, Jara C, Barnadas A, Fernández-Aramburo A, Sánchez-Rovira P, Amenedo M, Casado A; Spanish Breast Cancer Research Group..

J Clin Oncol. 2004 Jul 1;22(13):2587-93.

PMID:
15226326
11.

Bi-weekly docetaxel and gemcitabine regimen in her-2-negative and anthracycline-pretreated metastatic breast cancer patients: a multicenter phase II trial.

Murialdo R, Bertolotti F, Pastorino G, Mencoboni M, Bergaglio M, Folco U, Cinzia N, Vaira F, Simoni C, Canobbio L, Parodi M, Brema F, Ballestrero A.

Cancer Chemother Pharmacol. 2011 Oct;68(4):1009-16. doi: 10.1007/s00280-011-1570-7.

PMID:
21327683
12.

Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.

Sánchez-Rovira P, Jaén A, González E, Porras I, Dueñas MR, Medina B, Mohedano N, Fernández M, Martos M, Lozano A.

Clin Breast Cancer. 2000 Oct;1(3):226-32.

PMID:
11899647
13.

A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer.

Bayo J, Lomas M, Salvador J, Moreno A, Ruiz M, Rodríguez A, Fuentes J, Fernández-Freire A, Bernabé R, Fernández A.

Clin Transl Oncol. 2008 Dec;10(12):817-25.

PMID:
19068453
14.

Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer.

Murad AM.

Oncology (Williston Park). 2003 Dec;17(12 Suppl 14):26-32.

15.

Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer.

Blum JL, Dees EC, Chacko A, Doane L, Ethirajan S, Hopkins J, McMahon R, Merten S, Negron A, Neubauer M, Ilegbodu D, Boehm KA, Asmar L, O'Shaughnessy JA.

J Clin Oncol. 2006 Sep 20;24(27):4384-90.

PMID:
16926223
16.

High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer.

Stemmler J, Mair W, Stauch M, Papke J, Deutsch G, Abenhardt W, Dorn B, Kentenich C, Malekmohammadi M, Jackisch C, Leinung S, Brudler O, Vehling-Kaiser U, Stamp J, Heinemann V.

Oncology. 2005;68(1):71-8.

PMID:
15809523
17.

A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer.

Karachaliou N, Kouroussis Ch, Papakotoulas P, Kalbakis K, Tryfonidis K, Vardakis N, Poppis E, Georgoulias V, Mavroudis D.

Cancer Chemother Pharmacol. 2012 May;69(5):1345-52. doi: 10.1007/s00280-012-1824-z.

PMID:
22349809
18.
19.

Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a phase II trial.

Pelegrí A, Calvo L, Mayordomo JI, Florián J, Vázquez S, Arcusa A, Martn-Richard M, Bayo JL, Virizuela J, Carrasco E, Antón A; Spanish Group for Breast Cancer Research (GEICAM)..

Semin Oncol. 2004 Apr;31(2 Suppl 5):20-4.

PMID:
15199528
20.
Items per page

Supplemental Content

Support Center